We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+12.69%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$107M
AUM Growth
-$14.4M
Cap. Flow
-$401M
Cap. Flow %
-374.33%
Top 10 Hldgs %
58.32%
Holding
41
New
11
Increased
2
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
HELP
Cybin Inc
HELP
+$5.31M
2
ABVX
Abivax
ABVX
+$4.88M
3
CLSD
Clearside Biomedical
CLSD
+$3.73M
4
OTLK icon
Outlook Therapeutics
OTLK
+$2.52M
5
PYPD icon
PolyPid
PYPD
+$2.51M

Top Sells

Rank Stock Value
1
ATXS
Astria Therapeutics
ATXS
+$8.67M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$5.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.54M
4
CLRB icon
Cellectar Biosciences
CLRB
+$5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$3.97M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYO icon
1
Myomo
MYO
$38.6M
$8M 7.48%
2,447,740
+527,830
+27% +$1.91M
LYRA
2
DELISTED
LYRA THERAPEUTICS INC
LYRA
$7.12M 6.65%
22,890
-14,884
-39% -$3.97M
MDWD icon
3
MediWound
MDWD
$181M
$6.93M 6.47%
485,990
-120,761
-20% -$1.65M
OPTN
4
DELISTED
OptiNose
OPTN
$6.63M 6.2%
302,766
-22,939
-7% -$509K
XERS icon
5
Xeris Biopharma Holdings
XERS
$1.45B
$6.23M 5.82%
2,820,170
-723,515
-20% -$1.87M
CMPS
6
Compass Pathways
CMPS
$1.56B
$6.11M 5.71%
734,000
-64,500
-8% -$650K
HELP
7
Cybin Inc
HELP
$505M
$5.77M 5.39%
+367,368
New +$5.31M
ABVX
8
Abivax
ABVX
$10.8B
$5.41M 5.06%
+378,416
New +$4.88M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.2B
$5.25M 4.91%
300,000
-60,332
-17% -$1.17M
DCTH icon
10
Delcath Systems
DCTH
$416M
$4.96M 4.63%
1,038,828
– –
PROF
11
Profound Medical
PROF
$263M
$4.55M 4.25%
533,333
– –
VRNA
12
DELISTED
Verona Pharma
VRNA
$4.02M 3.76%
250,000
– –
CLSD
13
DELISTED
Clearside Biomedical
CLSD
$3.97M 3.71%
+172,840
New +$3.73M
OTLK icon
14
Outlook Therapeutics
OTLK
$194M
$3.72M 3.48%
+311,775
New +$2.52M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$3.42M 3.19%
287,985
-12,015
-4% -$160K
TRVI icon
16
Trevi Therapeutics
TRVI
$2.61B
$3.19M 2.99%
926,016
-936,409
-50% -$2.09M
VERU icon
17
Veru
VERU
$35.6M
$3.15M 2.94%
450,000
+50,000
+13% +$266K
UNCY icon
18
Unicycive Therapeutics
UNCY
$145M
$2.59M 2.42%
+187,965
New +$2.28M
CLRB icon
19
Cellectar Biosciences
CLRB
$20.2M
$2.47M 2.31%
20,716
-46,139
-69% -$5M
PYPD icon
20
PolyPid
PYPD
$83.8M
$1.91M 1.79%
+415,800
New +$2.51M
NSPR icon
21
InspireMD
NSPR
$31.5M
$1.63M 1.52%
686,062
-239,132
-26% -$645K
KPRX icon
22
Kiora Pharmaceuticals
KPRX
$11.3M
$1.62M 1.52%
+255,556
New +$1.43M
XAIR icon
23
Beyond Air
XAIR
$3.91M
$1.57M 1.47%
+2,259
New +$1.55M
TVRD
24
Tvardi Therapeutics
TVRD
$19.7M
$1.41M 1.32%
+43,025
New +$1.12M
FBIO icon
25
Fortress Biotech
FBIO
$109M
$1.22M 1.14%
607,797
– –
1
2

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Rosalind Advisors held 41 positions worth $107M, down 12% from $121M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Rosalind Advisors withdrew a net $401M in Q1 2024, closing 8 positions and reducing 13 holdings. Its most notable exit was Astria Therapeutics, an estimated $8.67M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Rosalind Advisors opened a new position in Cybin Inc worth $5.77M.

  • Rosalind Advisors's largest Q1 2024 buy was Cybin Inc: 367,368 shares worth $5.77M.
  • Rosalind Advisors added most to Myomo in Q1 2024, an estimated $1.91M increase.
  • Rosalind Advisors's biggest Q1 2024 reduction was Cellectar Biosciences, cutting an estimated $5M.
  • Rosalind Advisors fully exited Astria Therapeutics in Q1 2024, selling an estimated $8.67M.
  • Rosalind Advisors's ten largest holdings make up 58% of its $107M portfolio in Q1 2024.
  • Rosalind Advisors opened 11 new positions and closed 8 in Q1 2024.
  • Rosalind Advisors's portfolio value fell 12% quarter-over-quarter to $107M.

Based on Rosalind Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.